Shankar Siva1, Rodney J Ellis2, Lee Ponsky2, Bin S Teh3, Anand Mahadevan4, Alexander Muacevic5, Michael Staehler5, Hiroshi Onishi6, Peter Wersall7, Takuma Nomiya8, Simon S Lo2. 1. Division of Radiation Oncology & Cancer Imaging, Peter MacCallum Cancer Center, East Melbourne, Australia. 2. University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA. 3. Houston Methodist Hospital, Weil Cornell Medical College, Houston, TX, USA. 4. Beth Israel Deaconess Medical Center, Boston, MA, USA. 5. University of Munich Hospitals, Munich, Germany. 6. Department of Radiology, University of Yamanashi, Yamanashi, Japan. 7. Karolinska University Hospital/Karolinska Institute, Stockholm, Sweden. 8. National Institute of Radiological Sciences, Chiba, Japan.
Abstract
AIM: To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma. MATERIALS & METHODS: Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation. RESULTS: All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years. CONCLUSION: Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.
AIM: To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma. MATERIALS & METHODS: Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation. RESULTS: All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years. CONCLUSION: Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.
Authors: Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo Journal: Nat Rev Urol Date: 2017-06-20 Impact factor: 14.432
Authors: Rohann J M Correa; Belal Ahmad; Andrew Warner; Craig Johnson; Mary J MacKenzie; Stephen E Pautler; Glenn S Bauman; George B Rodrigues; Alexander V Louie Journal: Radiat Oncol Date: 2018-03-20 Impact factor: 3.481
Authors: Atallah Baydoun; Neha Vapiwala; Lee E Ponsky; Musaddiq Awan; Ali Kassaee; David Sutton; Tarun K Podder; Yuxia Zhang; Donald Dobbins; Raymond F Muzic; Bryan Traughber; Mitchell Machtay; Rodney Ellis Journal: J Appl Clin Med Phys Date: 2018-03-14 Impact factor: 2.102
Authors: Shankar Siva; Brent Chesson; Mathias Bressel; David Pryor; Braden Higgs; Hayley M Reynolds; Nicholas Hardcastle; Rebecca Montgomery; Ben Vanneste; Vincent Khoo; Jeremy Ruben; Eddie Lau; Michael S Hofman; Richard De Abreu Lourenco; Swetha Sridharan; Nicholas R Brook; Jarad Martin; Nathan Lawrentschuk; Tomas Kron; Farshad Foroudi Journal: BMC Cancer Date: 2018-10-23 Impact factor: 4.430